AlphAIAlphAI — Financial news for AI agents
proactiveinvestors.comSEP 152 min read$BIVI

BioVie Phase 2 trial shows bezisterim eases fatigue, cognitive symptoms in severe Long COVID cases

BioVie Inc. reported Phase 2 trial results for bezisterim, showing statistically significant symptom improvements in severe Long COVID patients with high baseline disease burden. The 203-patient trial evaluated 22 clinical outcomes and biomarkers. Subgroup analyses showed significant improvements in fatigue, cognitive impairment, and other symptoms. The company plans further Phase 3 trials to confirm these results. According to the company, bezisterim may become the first therapy for neurologica

Original reporting
proactiveinvestors.com
Published Sep 15, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BioVie Phase 2 trial shows bezisterim eases fatigue, cognitive symptoms in severe Long COVID cases — source image
Source · proactiveinvestors.com
Decision brief

The 30-second read

$BIVIBullishMed
01

Why it matters

Phase 2 data reduces clinical risk, likely prompting a price rally pending Phase 3 confirmation.

02

Market read

Positive trial data may attract speculative buying and increase sector momentum.

03

What to watch

Safety profile remains comparable to placebo, but long-term effects are unknown.

Relevance 8/10Novelty 9/10Timing: today

Background

BioVie is a Nasdaq‑listed biotech focused on treatments for post‑viral syndromes.

Company-level read

Ticker impact

$BIVIBullishHigh confidence
Context

BioVie reported Phase 2 trial results showing statistically significant improvements in fatigue and cognitive symptoms for high-burden Long COVID patients.

Expected impact

potential short-term upside as investors price in reduced clinical risk

Evidence & confidence

Statistically significant endpoints in a targeted subgroup suggest efficacy, lowering uncertainty before Phase 3.

Market effects

Sector

Long COVID therapeutic space may see increased investor interest.

Regional

U.S. biotech sector could benefit from renewed confidence in early-stage trials.

Global

Potential global demand for effective Long COVID treatments.

Counterpoint

What could challenge this read

Subgroup results may not translate to broader population; Phase 3 could fail.

Key entities

  • Company
    BioVie Inc

    Developer of bezierim for Long COVID.

  • Executive
    Cuong Do

    CEO of BioVie, quoted on trial significance.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 15
$BIVIMedAI 8/10

BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down

BioVie Inc. (BIVI) reported Phase 2 trial results for Bezisterim, showing significant improvements in Long COVID patients with high baseline fatigue and cognitive impairment. The drug demonstrated advantages over placebo on 21 of 22 endpoints and had a similar safety profile to placebo. BioVie plans to advance to Phase 3 trials. BIVI stock is down 8.23% in pre-market trading.

rttnews.com2 min
SEP 15
$BIVIMedAI 9/10

BioVie, Inc.: BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie Inc. (BIVI) reported positive Phase 2 trial results for bezisterim, showing statistically significant benefits in Long COVID patients with high baseline fatigue, cognitive impairment, and post-exertional malaise. The drug outperformed placebo on 21 of 22 endpoints in these subgroups, with a safety profile similar to placebo. The company plans to discuss the results in a conference call today.

finanznachrichten.de2 min
SEP 8
$BIVIMed

BioVie advances Parkinson’s Phase 3 development program with FDA engagement

BioVie Inc. (BIVI, BIVIW) announced plans to advance its Phase 3 trial for bezisterim in Parkinson’s disease, with an End-of-Phase 2 meeting requested with the FDA. The trial will focus on motor symptoms (MDS-UPDRS Part III) as the primary endpoint, with non-motor symptoms (MDS-UPDRS Part I) as a co-primary or secondary endpoint. Phase 2 results suggested greater benefits for patients with higher inflammation levels. The company expects to discuss the trial design with the FDA later this year an

proactiveinvestors.com2 min
AUG 7
$BIVIMedAI 8/10

BioVie stock sinks on Phase IIb Parkinson’s trial data

BioVie (NASDAQ: BIVI) shares fell after Phase IIb Parkinson’s trial data. On Aug. 6 the stock opened 33.3% lower at $1.36, briefly down nearly 60% to $0.82, then closed at $1.35, down 33.8% from Aug. 5. The data were released alongside a filing for a stock offering at $1.33 per share.

yahoo.com4 min